COVID-19 manifestations in people with Parkinson's disease: a USA cohort.
COVID-19
Parkinson’s disease
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
24
04
2021
accepted:
29
08
2021
revised:
16
07
2021
pubmed:
6
9
2021
medline:
23
2
2022
entrez:
5
9
2021
Statut:
ppublish
Résumé
With the explosion of COVID-19 globally, it was unclear if people with Parkinson's disease (PD) were at increased risk for severe manifestations or negative outcomes. To report on people with PD who had suspected or confirmed COVID-19 to understand how COVID-19 manifested in PD patients. We surveyed PD patients who reported COVID-19 to their Movement Disorders specialists at Columbia University Irving Medical Center and respondents from an online survey administered by the Parkinson's Foundation that assessed COVID-19 symptoms, general clinical outcomes and changes in motor and non-motor PD symptoms. Forty-six participants with PD and COVID-19 were enrolled. Similar to the general population, the manifestations of COVID-19 among people with PD were heterogeneous ranging from asymptomatic carriers (1/46) to death (6/46). The most commonly reported COVID-19 symptoms were fever/chills, fatigue, cough, weight loss, and muscle pain. Worsening and new onset of motor and non-motor PD symptoms during COVID-19 illness were also reported, including dyskinesia, rigidity, balance disturbances, anxiety, depression, and insomnia. We did not find sufficient evidence that PD is an independent risk factor for severe COVID-19 and death. Larger studies with controls are required to understand this further. Longitudinal follow-up of these participants will allow for observation of possible long-term effects of COVID-19 in PD patients.
Sections du résumé
BACKGROUND
BACKGROUND
With the explosion of COVID-19 globally, it was unclear if people with Parkinson's disease (PD) were at increased risk for severe manifestations or negative outcomes.
OBJECTIVES
OBJECTIVE
To report on people with PD who had suspected or confirmed COVID-19 to understand how COVID-19 manifested in PD patients.
METHODS
METHODS
We surveyed PD patients who reported COVID-19 to their Movement Disorders specialists at Columbia University Irving Medical Center and respondents from an online survey administered by the Parkinson's Foundation that assessed COVID-19 symptoms, general clinical outcomes and changes in motor and non-motor PD symptoms.
RESULTS
RESULTS
Forty-six participants with PD and COVID-19 were enrolled. Similar to the general population, the manifestations of COVID-19 among people with PD were heterogeneous ranging from asymptomatic carriers (1/46) to death (6/46). The most commonly reported COVID-19 symptoms were fever/chills, fatigue, cough, weight loss, and muscle pain. Worsening and new onset of motor and non-motor PD symptoms during COVID-19 illness were also reported, including dyskinesia, rigidity, balance disturbances, anxiety, depression, and insomnia.
CONCLUSION
CONCLUSIONS
We did not find sufficient evidence that PD is an independent risk factor for severe COVID-19 and death. Larger studies with controls are required to understand this further. Longitudinal follow-up of these participants will allow for observation of possible long-term effects of COVID-19 in PD patients.
Identifiants
pubmed: 34482434
doi: 10.1007/s00415-021-10784-3
pii: 10.1007/s00415-021-10784-3
pmc: PMC8418279
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1107-1113Subventions
Organisme : NIA NIH HHS
ID : R21 AG064596
Pays : United States
Organisme : NINDS NIH HHS
ID : R21 NS111176
Pays : United States
Informations de copyright
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Parkinsonism Relat Disord. 2020 Jun;75:126-127
pubmed: 32414669
J Am Geriatr Soc. 2020 May;68(5):926-929
pubmed: 32255507
Mov Disord. 2020 Jun;35(6):905-908
pubmed: 32347572
J Parkinsons Dis. 2020;10(4):1365-1377
pubmed: 32925107
Am J Epidemiol. 2003 Jun 1;157(11):1015-22
pubmed: 12777365
Geriatrics (Basel). 2020 Sep 18;5(3):
pubmed: 32962001
Ther Adv Chronic Dis. 2020 Aug 11;11:2040622320949423
pubmed: 32850107
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Int J Antimicrob Agents. 2020 Jun;55(6):106004
pubmed: 32361028
Mult Scler Relat Disord. 2020 Jul;42:102163
pubmed: 32388458
J Neurol. 2021 Aug;268(8):2666-2670
pubmed: 33098468
Pharmacol Rep. 2020 Dec;72(6):1538-1541
pubmed: 33040252
Mov Disord. 2020 Aug;35(8):1287-1292
pubmed: 32449528
Parkinsonism Relat Disord. 2020 Sep;78:134-137
pubmed: 32827969
NPJ Parkinsons Dis. 2021 Jan 21;7(1):10
pubmed: 33479241
JAMA Neurol. 2020 Jun 1;77(6):683-690
pubmed: 32275288
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
J Med Virol. 2021 Jan;93(1):110-111
pubmed: 32542661
MMWR Morb Mortal Wkly Rep. 2020 Apr 17;69(15):458-464
pubmed: 32298251
Med Hypotheses. 2020 Jul;140:109755
pubmed: 32361100
Mov Disord. 2021 Jan;36(1):1-10
pubmed: 33196119
Mov Disord. 2020 Jul;35(7):1089-1093
pubmed: 32484584